Nomic joins the HESI Global OASIS Consortium to Advance Human-Relevant Safety Assessment Through Proteomics
· media
AI Briefing
- * Nomic Bio Inc. partners with HESI Global OASIS Consortium for liver toxicity biomarker signature identification.
- * Large-scale protein profiling of human liver-derived cell models will be used.
- * Consortium aims for more predictive and human-relevant compound safety assessment approaches.
Source Summary
MONTREAL--(BUSINESS WIRE)--Nomic Bio Inc., today announced they will partner with the Health and Environmental Sciences Institute’s (HESI Global) Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium to identify biomarker signatures for liver toxicity using large-scale protein profiling of human liver-derived cell models. The OASIS Consortium is designed to support more predictive, efficient, and human-relevant approaches to compound safety assessment, consistent with the grow
Advertisement